Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.22

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been assigned an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $46.22.

ANAB has been the topic of several research reports. BTIG Research began coverage on shares of AnaptysBio in a report on Monday, February 26th. They set a “buy” rating and a $55.00 price objective on the stock. Wells Fargo & Company began coverage on AnaptysBio in a research note on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of AnaptysBio in a report on Tuesday, April 16th. Stifel Nicolaus initiated coverage on AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. Finally, Piper Sandler initiated coverage on AnaptysBio in a report on Friday, February 16th. They issued an “overweight” rating and a $80.00 target price on the stock.

AnaptysBio Price Performance

NASDAQ ANAB opened at $26.58 on Wednesday. The stock has a market capitalization of $726.17 million, a P/E ratio of -4.37 and a beta of -0.32. The business has a 50 day simple moving average of $22.93 and a 200 day simple moving average of $20.78. AnaptysBio has a one year low of $13.36 and a one year high of $27.50.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million for the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. Equities analysts expect that AnaptysBio will post -6.17 earnings per share for the current year.

Insider Activity

In other AnaptysBio news, CEO Daniel Faga sold 145,940 shares of the firm’s stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the transaction, the chief executive officer now directly owns 752,087 shares of the company’s stock, valued at approximately $17,132,541.86. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the insider now directly owns 3,240 shares in the company, valued at $81,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Daniel Faga sold 145,940 shares of the company’s stock in a transaction dated Friday, March 22nd. The stock was sold at an average price of $22.78, for a total value of $3,324,513.20. Following the completion of the transaction, the chief executive officer now owns 752,087 shares of the company’s stock, valued at $17,132,541.86. The disclosure for this sale can be found here. Insiders have sold a total of 153,940 shares of company stock worth $3,513,773 over the last ninety days. Company insiders own 35.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. First Light Asset Management LLC lifted its stake in AnaptysBio by 56.4% in the fourth quarter. First Light Asset Management LLC now owns 1,237,178 shares of the biotechnology company’s stock worth $26,500,000 after purchasing an additional 446,372 shares during the last quarter. Great Point Partners LLC raised its holdings in AnaptysBio by 9.2% during the 4th quarter. Great Point Partners LLC now owns 976,981 shares of the biotechnology company’s stock valued at $20,927,000 after buying an additional 82,648 shares during the last quarter. Eventide Asset Management LLC purchased a new stake in AnaptysBio during the 3rd quarter valued at $7,669,000. Franklin Resources Inc. grew its holdings in AnaptysBio by 22.7% in the 4th quarter. Franklin Resources Inc. now owns 405,115 shares of the biotechnology company’s stock worth $8,678,000 after acquiring an additional 75,025 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its stake in shares of AnaptysBio by 4.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 206,785 shares of the biotechnology company’s stock worth $3,714,000 after purchasing an additional 8,064 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.